|
Compendia Bioscience, Inc. is dedicated to gathering the world's high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to ultimately improve the lives of patients.
Oncomine 4.3 is now available!
Oncomine 4.3 provides major data improvements that facilitate identification, interpretation and communication of results.
Easily differentiate large genomic regions of change from localized aberrations
Filter results to only those with biological and statistical significance
Amplification and deletion results across 3,490 cell lines and tumors
These new capabilities provide significant improvements in the assessment of cancer targets, prioritization of findings and the communication of results to your research teams.
 Compendia Bioscience's flagship product, Oncomine™, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of success.
Compendia provides product offerings for both research (non-profit) and commercial organizations.
|
MORE
MORE
Show Site